about
Treatment of Cushing disease: overview and recent findingsParathyroid hormone pulsatility: physiological and clinical aspectsGlucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiencyPituitary disorders and osteoporosisMultiscale alterations in bone matrix quality increased fragility in steroid induced osteoporosisLasting consequences of traumatic events on behavioral and skeletal parameters in a mouse model for post-traumatic stress disorder (PTSD).Stress hormone masculinizes female morphology and behaviour.Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus.Preadipocyte factor-1 is associated with marrow adiposity and bone mineral density in women with anorexia nervosaOsteoporosis prophylaxis in patients receiving chronic glucocorticoid therapyA normal reference of bone mineral density (BMD) measured by dual energy X-ray absorptiometry in healthy thai children and adolescents aged 5-18 years: a new reference for Southeast Asian PopulationsThe osteogenesis-promoting effects of alpha-lipoic acid against glucocorticoid-induced osteoporosis through the NOX4, NF-kappaB, JNK and PI3K/AKT pathways.A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass.Nonclassic congenital adrenal hyperplasiaBone quality, as measured by trabecular bone score in patients with adrenal incidentalomas with and without subclinical hypercortisolism.Col3.6-HSD2 transgenic mice: a glucocorticoid loss-of-function model spanning early and late osteoblast differentiation.Teriparatide induced delayed persistent hypercalcemiaAn N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excessThe influence of corticosteroid treatment on the OPG/RANK/RANKL pathway and osteocalcin in patients with pemphigus.Mutiple Spontaneous Rib Fractures in Patient with Cushing's Syndrome.The negative impact of single prolonged stress (SPS) on bone development in mice.Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?Increased bone marrow fat in anorexia nervosaSkeletal health of children and adolescents with inflammatory bowel disease.Bone loss and fractures in multiple sclerosis: focus on epidemiologic and physiopathological features.Bone-immune cell crosstalk: bone diseases.Plumbagin protects against glucocorticoid-induced osteoporosis through Nrf-2 pathway.Treatment Options in Cushing's Disease.Management of severe osteoporosis.Incidence of Symptomatic Vertebral Fractures Among Newly Diagnosed Autoimmune Diseases Initiating Glucocorticoid Therapy.Treatment of glucocorticoid-induced osteoporsisGlucocorticoid-induced osteoporosis: treatment update and review.Body composition and skeletal health: too heavy? Too thin?Inhibition of Pref-1 (preadipocyte factor 1) by oestradiol in adolescent girls with anorexia nervosa is associated with improvement in lumbar bone mineral densityGlucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralizationCushing's syndrome: aftermath of the cure.Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects.Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.Body composition in multiple sclerosis.Expression of HCA2 Receptors in Femoral Epiphysis and Metaphysis of Rats with Dexamethasone-Induced Osteoporosis
P2860
Q24626819-61996BE5-0337-467F-B11D-8B98D196650EQ26798180-EC74B204-89B3-42AA-A1D0-419BCBD159D4Q26821908-968B3BAF-7AE2-4ECF-BD69-DDE0619AE79FQ27008465-4359C14C-9D10-40D9-809C-3837F05E9502Q27324822-D476BC27-1B68-49E3-AC07-2799E516AA21Q28482465-1C6B3622-E821-40C8-B6B6-C9032464035AQ30498037-ED1B8449-5BF1-43F6-B023-39797AFB48FCQ33375577-E670D873-ACA4-44C1-B0BC-C2A2C649FC22Q33586733-268779C9-D158-4B78-98AA-634D0424000DQ33619648-51B1F1F9-F780-47D6-8DDC-616D5D8AEBCCQ33644384-1303EC3A-6567-4D5D-8C19-C38B51E441B3Q33794181-AE6EDBC8-4778-4FC8-91A9-13F99C8E1421Q33923332-3F4D33B3-24B8-4798-BA4A-82BF92D62598Q34021657-70A30FAD-5C28-4117-A72F-EDFC206C3057Q34031744-0AE445D0-8612-4EB9-AF1F-3341216158D7Q34079475-FDEB4879-835C-46A0-BD10-EF781486856FQ34118834-DBD61E7B-B943-4322-AC09-690582553D27Q34316496-AC531535-FD05-48C2-9EB1-2FEAB823C1A5Q34457946-F3A0ADC3-0609-400E-AF2E-6DAEC30C872EQ34627986-07F15D5B-3C54-4F27-B599-B2782F3F6153Q34727297-0D00A9D6-0C80-4A0B-B62E-C60F0A23FFEEQ34753158-80D7E458-8C88-49E0-96CC-E8F19F45B6FEQ34968288-C7ED35D3-0AB8-470B-AD68-89D5FA66C44AQ35065044-B70BD506-C213-4653-9150-B50E22A92296Q35147216-ADC4B821-859E-470A-B339-548BCEE25F3EQ35592362-032A12F8-D2FC-46F3-B270-DD88E8F641B0Q35725177-B5476E02-FE5F-4223-B761-8381A50B4E35Q35740882-0B368BAF-1DC6-421E-AF4C-930360C5EED2Q35852252-BAD1A45B-8118-4D3C-B955-F8AA2983211DQ35858075-D1A6529B-A1A9-41A1-AF09-28FE91272DD6Q36056932-7C4D0D39-C5EF-4EAE-8E59-4B94BC8B718EQ36059394-31BB1B5E-568C-472E-850F-63E3341360A6Q36642489-FB64AC6D-C185-4B25-AB9A-3429CF4B2BC5Q36807580-EBFF50D5-07CE-4DC3-935A-375C05AA1912Q37003240-86CC0180-FA2C-4C35-BFB8-A74E79070832Q37062081-5F90AB01-447E-4298-A967-161042D5DC50Q37062092-340B42E2-10A5-49B2-8EB9-F6F5646EFB6EQ37072338-9B000E98-191E-4A7A-BB7D-FF4FDCEDD4C4Q37082402-79439A56-1573-43A3-8E3F-6EA7C8C70AE9Q37099608-8F394DCE-634D-46EF-916C-E660352A5188
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Glucocorticoid-induced osteoporosis: an update.
@ast
Glucocorticoid-induced osteoporosis: an update.
@en
type
label
Glucocorticoid-induced osteoporosis: an update.
@ast
Glucocorticoid-induced osteoporosis: an update.
@en
prefLabel
Glucocorticoid-induced osteoporosis: an update.
@ast
Glucocorticoid-induced osteoporosis: an update.
@en
P2093
P1476
Glucocorticoid-induced osteoporosis: an update.
@en
P2093
Alberto Angeli
Andrea Giustina
Ernesto Canalis
Gherardo Mazziotti
P304
P356
10.1016/J.TEM.2006.03.009
P577
2006-05-01T00:00:00Z